Fine-tuning affinity and spacer design enhances T cell potency in DLL3 and BCMA CAR T cells

Chimeric antigen receptor (CAR)-modified T cells have garnered substantial attention due to their clinical success, culminating in six Food and Drug Administration-approved therapies for hematological malignancies. Notably, CD19-specific CAR T cell therapies have achieved remarkable clinical efficac...

Cijeli opis

Bibliografski detalji

Glavni autori:	Nicholas Mazzanti, Ninkka Tamot, Andrea Francese, Jinquan Luo, M. Jack Borrok, Julie Rossillo, Joseph Plummer, Gauri Anand Patwardhan, Chi Shing Sum, Michael Ports, Kara L. Spiller, Madhusudhanan Sukumar
Format:	Artigo
Jezik:	Inglês
Izdano:	Taylor & Francis Group 2026-12-01
Serija:	mAbs
Teme:	Affinity CAR CAR design chimeric antigen receptor spacer domain
Online pristup:	https://www.tandfonline.com/doi/10.1080/19420862.2025.2602989
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!